Characterization of the endotheliopathy, innate-immune activation and hemostatic imbalance underlying CAR-T cell toxicities: laboratory tools for an early and differential diagnosis
Source : https://jitc.bmj.com/content/11/4/e006365
Background Chimeric antigen receptor (CAR)-T cell-based immunotherapy constitutes a revolutionary advance for treatment of relapsed/refractory hematological malignancies. Nevertheless, cytokine release and immune effector cell-associated neurotoxicity syndromes are life-threatening toxicities in...
Conclusions: This study provides relevant contributions to the current knowledge of the CAR-T cell toxicities pathophysiology. Markers of endotheliopathy, innate immunity activation and hemostatic imbalance appear as potential laboratory tools for their prediction, severity and differential diagnosis.
Management of Relapsed-Refractory Multiple Myeloma in the Era of Advanced Therapies: Evidence-Based Recommendations for Routine Clinical Practice - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37046821/
Multiple myeloma (MM) is the second most common hematologic malignancy in adults worldwide. Over the past few years, major therapeutic advances have improved progression-free and overall survival, as well as...
Relevance: In this review, we will focus on the treatment paradigm of relapsed/refractory MM (RRMM) in the era of advanced therapies emphasizing the available novel modalities that have recently been incorporated into routine practice, such as chimeric antigen receptor T-cell therapy, bispecific antibodies, and other promising approaches. We...
Outcomes with panobinostat in heavily pretreated multiple myeloma patients
Source : https://www.sciencedirect.com/science/article/abs/pii/S0093775423000398?via=ihub
Available online 24 March 2023 Author links open overlay panel Darren Pan a , , , , , , , Show more is an . Previously published studies of panobinostat...
Conclusions: Panobinostat-based combination therapies were well-tolerated and yielded modest response rates and CBRs in patients whose disease had been heavily pretreated, over half of whom had disease classified as triple class refractory. Rather than being applied to a broad-based relapsed/refractory multiple myeloma population, the future...
Treatment pattern and clinical outcomes in multiple myeloma patients in Japan using the Medical Data Vision claims database
Source : https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0283931
Multiple myeloma therapy has made remarkable progress with the advent of new drugs. We explored the treatment pattern and outcomes in Japanese patients with multiple myeloma using the Medical Data...
Conclusions/Relevance: Thus, this study revealed that recent diversification of treatment options is preferred and contributes to improved outcomes in the clinical practice of multiple myeloma in Japan.
RNA silencing of GM-CSF in CAR-T cells reduces the secretion of multiple inflammatory cytokines - Investigational New Drugs
Source : https://link.springer.com/article/10.1007/s10637-023-01344-9
Chimeric antigen receptor T (CAR-T) cell therapy has become a research hotspot in the field of hematological malignancies. However, CAR-T cell therapy can lead to immunotherapy-associated side effects including cytokine...
Conclusion: We introduced a new method to reduce GM-CSF secretion from CAR-T cells by inserting the GM-CSF shRNA-expression cassette in the CAR vector. This approach can be applied on any newly-developed CAR construct. The manufacture of GM-CSFKD CAR-T cells does not require repeated transfection, and the knockdown efficiency is more...